Overall, in hemophilia mice, GalNAc-conjugated ASOs targeting eRF1 and eRF3a worked in synergy with the small molecular read-through drug geneticin, significantly increasing production of full-length hFIX protein, which results in improved plasma FIX activity. The gene discussed is GSPT1; the disease is hemophilia.